Over the past 12 months, 3 insiders at Terns Pharmaceuticals, Inc. filed 12 open-market SEC Form 4 transactions on TERN: 0 purchases worth $0 and 12 sales worth $7.0M. Insiders have been net sellers over this period. The most recent filing was on Mar 16, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 26 | Amy L. BurroughsChief Executive Officer | SELL | 11.8K | $47.30 | $550K |
| Feb 17, 26 | Amy L. BurroughsChief Executive Officer | SELL | 8.2K | $39.80 | $320K |
| Jan 15, 26 | Amy L. BurroughsChief Executive Officer | SELL | 61.2K | $37.53 | $2.3M |
| Jan 5, 26 | Amy L. BurroughsChief Executive Officer | SELL | 71.3K | $38.10 | $2.7M |
| Jan 2, 26 | Emil KuriakoseChief Medical Officer | SELL | 955 | $39.60 | $37K |
| Nov 4, 25 | Jill M. QuigleyDirector | SELL | 24.5K | $18.00 | $441K |
| Oct 1, 25 | Emil KuriakoseChief Medical Officer | SELL | 944 | $7.85 | $7K |
| Jul 1, 25 | Emil KuriakoseChief Medical Officer | SELL | 853 | $4.27 | $4K |
| Jun 27, 25 | Andrew GengosChief Financial Officer | BUY | 5.0K | $3.93 | $20K |
| Jun 25, 25 | Amy L. BurroughsChief Executive Officer | BUY | 23.3K | $3.87 | $90K |
| Jun 16, 25 | Andrew GengosChief Financial Officer | BUY | 5.0K | $3.95 | $20K |
| Jun 13, 25 | Andrew GengosChief Financial Officer | BUY | 5.0K | $3.75 | $19K |
| Apr 1, 25 | Emil KuriakoseChief Medical Officer | SELL | 952 | $2.49 | $2K |
| Jan 6, 25 | Jill M. QuigleyDirector | SELL | 8.8K | $5.79 | $51K |
| Jan 6, 25 | Mark J. VignolaChief Financial Officer | SELL | 9.1K | $5.80 | $53K |
| Jan 2, 25 | Emil KuriakoseChief Medical Officer | SELL | 4.5K | $5.71 | $26K |
| Jan 2, 25 | Jill M. QuigleyDirector | SELL | 6.2K | $5.72 | $36K |
| Jan 2, 25 | Mark J. VignolaChief Financial Officer | SELL | 8.1K | $5.72 | $46K |
| Dec 5, 24 | Amy L. BurroughsChief Executive Officer | BUY | 15.4K | $7.15 | $110K |
| Nov 30, 24 | Amy L. BurroughsChief Executive Officer | BUY | 510 | $5.11 | $3K |
| Nov 30, 24 | Melita Sun JungChief Business Officer | BUY | 2.3K | $5.11 | $11K |
| Sep 12, 24 | Hongbo LuDirector | BUY | 285.7K | $10.50 | $3.0M |
| Sep 10, 24 | Mark J. VignolaChief Financial Officer | SELL | 10.0K | $11.00 | $110K |
| Sep 9, 24 | Jill M. QuigleyDirector | SELL | 17.2K | $10.00 | $172K |
| Aug 2, 24 | Jill M. QuigleyDirector | SELL | 8.9K | $7.50 | $66K |
| Aug 1, 24 | Jill M. QuigleyDirector | SELL | 6.1K | $7.68 | $47K |
| Jul 16, 24 | Carl L GordonDirector,TenPercentOwner | SELL | 4.0K | $10.00 | $40K |
| Jul 16, 24 | Orbimed Genesis Gp LlcDirector,TenPercentOwner | SELL | 4.0K | $10.00 | $40K |
| Jul 16, 24 | Jill M. QuigleyDirector | SELL | 400 | $10.00 | $4K |
| Jul 15, 24 | Carl L GordonDirector,TenPercentOwner | SELL | 39.4K | $10.00 | $394K |
| Jul 15, 24 | Orbimed Genesis Gp LlcDirector,TenPercentOwner | SELL | 39.4K | $10.00 | $394K |
| Jul 15, 24 | Jill M. QuigleyDirector | SELL | 14.4K | $10.00 | $144K |
| May 31, 24 | Mark J. VignolaChief Financial Officer | BUY | 4.8K | $4.44 | $21K |
| May 31, 24 | Seokho Bryan YoonCOO and General Counsel | BUY | 4.8K | $4.44 | $21K |
| Apr 3, 24 | Vivo Opportunity, LlcTenPercentOwner | SELL | 103.9K | $6.20 | $644K |
| Apr 2, 24 | Vivo Opportunity, LlcTenPercentOwner | SELL | 76.3K | $6.65 | $508K |
| Apr 1, 24 | Vivo Opportunity, LlcTenPercentOwner | SELL | 136.3K | $6.99 | $952K |
| Nov 30, 23 | Mark J. VignolaChief Financial Officer | BUY | 743 | $3.78 | $3K |
| Nov 30, 23 | Seokho Bryan YoonCOO and General Counsel | BUY | 743 | $3.78 | $3K |
| May 31, 23 | Senthil Vel SundaramChief Executive Officer | BUY | 2.1K | $1.41 | $3K |
| May 31, 23 | Mark J. VignolaChief Financial Officer | BUY | 10.0K | $1.41 | $14K |
| May 31, 23 | Seokho Bryan YoonCOO and General Counsel | BUY | 10.0K | $1.41 | $14K |
| Dec 23, 22 | Carl L GordonDirector,TenPercentOwner | BUY | 137.9K | $7.25 | $1.0M |
| Dec 23, 22 | Hongbo LuDirector | BUY | 758.6K | $7.25 | $5.5M |
| Dec 23, 22 | Orbimed Genesis Gp LlcDirector,TenPercentOwner | BUY | 137.9K | $7.25 | $1.0M |
| Dec 23, 22 | Vivo Opportunity Fund Holdings, L.p.TenPercentOwner | BUY | 758.6K | $7.25 | $5.5M |
| Nov 23, 22 | Oriental Spring Venture LtdTenPercentOwner | SELL | 1.00M | $5.50 | $5.5M |
| Sep 7, 22 | Hongbo LuDirector | BUY | 600.0K | $3.60 | $2.2M |
| Sep 7, 22 | Vivo Opportunity, LlcTenPercentOwner | BUY | 600.0K | $3.60 | $2.2M |
| Aug 16, 22 | Carl L GordonDirector,TenPercentOwner | BUY | 2.47M | $2.42 | $6.0M |
Over the past 12 months, insiders at Terns Pharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 12 sales worth $7.0M on TERN, which makes them net sellers over the period. The most recent Form 4 was filed on Mar 16, 26.
The largest recent open-market TERN insider purchase in our data was $6.0M by Carl L Gordon, Director,TenPercentOwner, filed on Aug 16, 22.
3 different insiders at Terns Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on TERN over the last 12 months.
InsiderTape plots every TERN insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Terns Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →